Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed
countries. We conducted a multi-stage genome-wide association study for PrCa and …

BACKGROUND Currently used prognostic markers are limited in their ability to accurately
predict disease progression among patients with localized prostate cancer. We examined 23 …

Background Many studies on prostate cancer (PCa) germline variants have been published
in the last 15 years. This review critically assesses their clinical validity and explores their …

Prostate specific antigen (PSA) is widely used as a diagnostic biomarker for prostate cancer
(PC). However, due to its low predictive performance, many patients without PC suffer from …

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified
more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data …

Context Given the pitfalls of prostate-specific antigen (PSA) testing for screening men with
asymptomatic prostate cancer (PCa), a number of novel biomarkers have recently been …

Background Several polygenic risk score (PRS) methods are available for measuring the
cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). Their …

Prostate cancer risk is influenced by rare and common germline variants. We examined the
aggregate association of rare germline pathogenic/likely pathogenic/deleterious (P/LP/D) …

Polygenic risk scores (PRSs) for a variety of diseases have recently been shown to have
relative risks that depend on age, and genetic relative risks decrease with increasing age. A …

Genome-wide association studies (GWAS) have identified multiple common genetic variants
associated with an increased risk of prostate cancer (PrCa), but these explain less than one …